NeuCyte is an early-stage biotech focused on advancing the early phases of CNS drug discovery programs for Lead Compound Optimization.
NeuCyte has raised $500K in total funding. The most recent round was Grant. The last funding was announced in August 2023.
NeuCyte's investors include Leaguer Venture Capital, Cowin Venture, Wisemont Capital, National Institute of Health.
NeuCyte is headquartered in Mountain View, United States.
NeuCyte is an early-stage biotech focused on advancing the early phases of CNS drug discovery programs for Lead Compound Optimization.
NeuCyte is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NeuCyte — Funding & Investors." VCBacked, August 14, 2023, https://www.vcbacked.co/company/neucyte. Accessed August 14, 2026.
VCBacked. (2023). NeuCyte — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/neucyte
{{cite web |title=NeuCyte — Funding & Investors |url=https://www.vcbacked.co/company/neucyte |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated